Signal
AMCP Report Highlights Payer Uncertainty Over ESR1 Biomarker Testing in Breast Cancer
- Category
- · Report · Global
- Date
- October 16, 2026
- Source
- OVUM
Summary
New market insights from the Academy of Managed Care Pharmacy reveal significant coverage gaps and clinical hesitation regarding ESR1 mutation testing, despite the emergence of oral selective estrogen receptor degraders for advanced metastatic breast cancer.
The report adds hard numbers — market size, share, and economics — for Oncology and Diagnostics. Check the method and the data year before using the numbers.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.